Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%
ECONOMY & POLICY

Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. 

For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. 

Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. 

Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. 

(BSE)     

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. (BSE)     

Next Story
Technology

Building Faster, Smarter, and Greener!

Backed by ULCCS’s century-old legacy, U-Sphere combines technology, modular design and sustainable practices to deliver faster and more efficient projects. In an interaction with CW, Rohit Prabhakar, Director - Business Development, shares how the company’s integrated model of ‘Speed-Build’, ‘Smart-Build’ and ‘Sustain-Build’ is redefining construction efficiency, quality and environmental responsibility in India.U-Sphere positions itself at the intersection of speed, sustainability and smart design. How does this translate into measurable efficiency on the ground?At U..

Next Story
Infrastructure Transport

Smart Roads, Smarter India

India’s infrastructure boom is not only about laying more kilometres of highways – it’s about building them smarter, safer and more sustainably. From drones mapping fragile Himalayan slopes to 3D machine-controlled graders reducing human error, technology is steadily reshaping the way projects are planned and executed. Yet, the journey towards digitisation remains complex, demanding not just capital but also coordination, training and vision.Until recently, engineers largely depended on Survey of India toposheets and traditional survey methods like total stations or DGPS to prepare detai..

Next Story
Real Estate

What Does DCPR 2034 Mean?

The Maharashtra government has eased approval norms for high-rise buildings under DCPR 2034, enabling the municipal commissioner to sanction projects up to 180 m on large plots. This change is expected to streamline approvals, reduce procedural delays and accelerate redevelopment, drawing reactions from developers, planners and industry experts about its implications for Mumbai’s vertical growth.Under the revised DCPR 2034 rules, buildings on plots of 2,000 sq m or more can now be approved up to 180 m by the municipal commissioner, provided structural and geotechnical reports are certified b..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?